The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correction to Kaplan et al., N Engl J Med 352(3):301-304 January 20, 2005.

Correction
PreviousPrevious
Volume 352:1163 March 17, 2005 Number 11
NextNext

Oral Erythromycin and the Risk of Sudden Death

 

This Article
- PDF
-PDA Full Text

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Kaplan, E. L.
Oral Erythromycin and the Risk of Sudden Death . In the letter by Schoenholtz, lines 1 through 4 of the second full paragraph on page 302 should have read, "Between thioridazine and haloperidol are the `atypical' drugs, which are far more potentiating of cytochrome P-450 inhibitors than haloperidol," rather than "which are far more potent blockers of cytochrome P-450 inhibitors than haloperidol," as printed.



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.